FDA - Spark Newswire

1 minute read

Opiant Pharma Stock Surges On Positive Nasal Nalmefene Data In Opioid Overdose Study

Today, 9:15 PM

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) announced top-line results from its confirmatory pharmacokinetic study for OPNT003, nasal nalmefene, for opioid overdose. The 68-subject…

OPNT

1 minute read

Jazz Pharmaceuticals Announces Health Canada Approval Of Vyxeos

By Bill Haddad

Today, 9:15 PM

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the Health Canada approval and availability of Vyxeos® (daunorubicin and cytarabine liposome for injection) for the treatment of adults with newly diagnosed

JAZZ

5 minute read

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend

By Shanthi Rexaline

Today, 9:15 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6)

ABCL

2 minute read

Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results In Recessive Dystrophic Epidermolysis Bullosa At The Society For Pediatric Dermatology 46th Annual Meeting

By Bill Haddad

Today, 9:15 PM

Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical trial results up to six years following treatment with Abeona's investigational

ABEO

3 minute read

NGM Bio Announces Initiation Of Phase 1/2 Clinical Study Of NGM707 For Treatment Of Advanced Solid Tumors

By Bill Haddad

Today, 9:15 PM

--NGM707, a ILT2/ILT4 dual antagonistic antibody, is engineered to reverse myeloid suppression with the goal of improving patient immune responses to tumors-- --Study to evaluate potential of NGM707 in patients

NGM

1 minute read

Myovant Sciences Ltd On July 6 Submitted A SNDA To FDA For Once-Daily MYFEMBREE

By Bill Haddad

Today, 9:15 PM

-Reuters

MYOV

1 minute read

Eli Lilly, Boehringer Ingelheim Tout Heart Failure Win For Jardiance

By Vandana Singh

Today, 9:15 PM

Boehringer Ingelheim and Eli Lilly And Co (NYSE:LLY) have announced the topline results from the EMPEROR-Preserved Phase 3 trial of Jardiance (empagliflozin). Jardiance…

LLY

2 minute read

ChemoCentryx Stock Is Approaching A Key Level

By Tyler Bundy

Today, 9:15 PM

ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmic yutoantibody associated vasculitis. The U.S.

CCXI

2 minute read

What’s Next For Ocugen Stock As It Nears Key Resistance Level?

By Tyler Bundy

Today, 9:15 PM

Ocugen Inc. (NASDAQ: OCGN) shares traded higher Tuesday after the company announced that its coronavirus vaccine co-development partner Bharat Biotech reported Phase 3 results demonstrating 77.8% protection against overall disease.

OCGN